Method for detecting the antiaggregatory effect of vasoactive substances, specifically of inhibitors of phosphodiesterase and/or cyclooxygenase

US4983514A · kind A · utility

Assignee

• Hoechst GmbH · DE

Inventors

• Klaus-Ulrich Weithmann · Hofheim, DE
• Dirk Seiffge · Hochheim, DE

Key dates

• Filing date: May 20, 1988
• Grant date: Jan 8, 1991
• Expiry date: May 20, 2008

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/34
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body by PA0 sampling blood, PA0 addition of (A) and/or (B) to the blood sample--if not already present therein, in unchanged or in metabolized form, as a consequence of previous administration, PA0 where appropriate removal of the erythrocytes and leukocytes and PA0 initiation--preferably by addition of an aggregation inducer--and measurement of the platelet aggregation, the method comprises (A) also being added--if only (B) has been administered or added up till then--or (B) also being added--if only (A) has been administered or added up till then--and at least one prostaglandin (C) being added, before, or no later than at, the initiation of the platelet aggregation, so that the initiation and measurement of the platelet aggregation takes place in the presence of the ternary combination of (A), (B), each in the unchanged or in metabolized form, and (C). Suitable as (A) are preferably compounds with a xanthine or pyrimidopyrimidine structure and as (B) is preferably O-acetylsalicylic acid. The method replaces elaborate and complicated tests …